360 Stem Cell & Regenerative Medicine Newsletter - March 18, 2016

 weSRCH's Best of the Internet Award
  18th-Mar-2016
 266

Share: FacebookTwitterLinkedIn

360 Stem Cell & Regenerative Medicine Newsletter - Mar. 18, 2016

Featured video from the New York Stem Cell Foundation:

GEN: For stem cells, half a genome is better than none
Scientists from The Hebrew University of Jerusalem, Columbia University Medical Center, and The New York Stem Cell Foundation (NYSCF) Research Institute have created a new type of embryonic stem cell that carries a single copy of the human genome instead of the two copies typically found in normal stem cells. The scientists reported their findings (“Derivation and Differentiation of Haploid Human Embryonic Stem Cells”) in Nature. Read article.
360 comment: This study has profound scientific and clinical implications. For additional information, read press release here.

World Stem Cell Summit

BREAKING NEWS: Major new bipartisan initiative, the REGROW Act, will provide tools for the FDA to accelerate safe and effective regenerative cell therapies
Bipartisan legislation mirroring the Bipartisan Policy Center (BPC) Report, Advancing Regenerative Cellular Therapy: Medical Innovation for Healthier Americans, was introduced in the Senate and the House, by Senators Mark Kirk (R-IL), Joe Manchin (D-WV), and Susan Collins (R-ME) (S. 2689) and Reps. Mike Coffman (R-CO), Mark Takai (D-HI), and Morgan Griffith (R-VA) (H.R. 4762).

Here are the relevant links:


360 Editor’s comment: The Regenerative Medicine Foundation, publisher of this newsletter, applauds this important initiative. Recent scientific advances and the convergence of technologies mandate that the FDA have the tools to forge a new, safe pathway for regenerative cell therapies. We can’t afford to wait a decades for new treatment plans and cures. The REGROW Act opens a safe and accelerated pathway for certain cell therapies. In addition, the REGROW Act requires the FDA to collaborate with stakeholders to develop standards that will lead to manufacturing processes and controls for safe regenerative medicine products. Bottom line- the REGROW Act is a timely leap forward that will benefit patients.

The New York Family Office Meetings

STAT: Clash of scientific titans: CRISPR hits the courts, with money and prestige at stake
Here’s a “crisp” analysis about the patent rights pertaining to the key to gene editing- CRISPR-Cas 9. It’s all the power and might of the University of California versus the very formidable Broad Institute and MIT. The court battle could take years. Will patients suffer? The writer wryly observes, “While most patents are dogs, some exceptional ones are financial gushers.” Read article.

Help4HD

UPI: Osteoporosis in mice reversed with stem cell therapy
“Donor stem cells injected into mice with age-related osteoporosis led to a restoration of normal bone structure, according to researchers at the University of Toronto.
The proof-of-concept study found a single injection of mesenchymal stem cells from healthy mice to those with osteoporosis led to the "surprising" development of normal bone structure. MSCs are capable of becoming any cell, including bone cells, and donors do not need to match recipients because the cells won't be rejected. With just one widely available treatment for osteoporosis, which is effective for about two years, researchers said the MSCs could be used to prevent the progressive condition.” The study was published in Stem Cells Translational Medicine, the official journal partner of the Regenerative Medicine Foundation. Read article.

CBR

Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine
“Capricor Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics announced that the Board of the California Institute for Regenerative Medicine (CIRM) has approved a grant award to Capricor for approximately $3.38 million to support the Company's Phase I/II HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) clinical trial investigating CAP-1002, a cardiac cell therapy, in patients with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.” Read full media release.

CCRM

Cedars-Sinai: Researchers find that immune cells play unexpected role in Lou Gehrig's Disease- Findings raise hope for new ALS treatments that target immune cell dysfunction
Hope for the ALS community. Congratulations to Dr. Clive Svendsen and his team. Read media release.

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute
Regenerative Medicine Foundation



Bernard Siegel's TedX talk "Stem Cells and the Transformative Power of Hope"

About GPI

The nonprofit Genetics Policy Institute and Regenerative Medicine Foundation seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn


World Stem Cell Summit & Regmed Capital Conference Overview

Domain: Medical
Category: Biology

Recent Newsletters

12 March, 2019
10 October, 2018
15 February, 2018